Focus: Artiva Biotherapeutics is a San Diego-based biotech focused on allogeneic NK cell therapies for oncology and autoimmune diseases. The company is advancing a differentiated cell therapy platform with multiple programs in clinical development.
Profile data last refreshed 55m ago · AI intelligence enriched 2w ago
Cooling — net -16 jobs in 30d
5 added, 21 removed. Slower than typical.
Recent layoff filing — 131 affected
Source: state DOL filings via Big Local News
Artiva offers high technical upside in a cutting-edge modality with recent regulatory validation, but pre-revenue biotech status demands comfort with clinical-stage risk and capital-dependent timelines.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Artiva Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Artiva Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
T-Cell Lymphoma Clinical Trial Drug Development Pipeline Expands with Contributions from 90+ Key Companies | DelveInsight - StreetInsider
T-Cell Lymphoma Clinical Trial Drug Development Pipeline Expands with Contributions from 90+ Key Companies | DelveInsight StreetInsider
Rheumatoid Arthritis Clinical Trial Drug Development Pipeline - openPR.com
Rheumatoid Arthritis Clinical Trial Drug Development Pipeline openPR.com
Analysts Conflicted on These Healthcare Names: Dexcom (DXCM) and Fate Therapeutics (FATE) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Dexcom (DXCM) and Fate Therapeutics (FATE) The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks The Globe and Mail
4th Cell Therapy for Autoimmune Disease Summit - pharmaphorum
4th Cell Therapy for Autoimmune Disease Summit pharmaphorum
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - Simply Wall Street
Have Insiders Sold Artiva Biotherapeutics Shares Recently? Simply Wall Street
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
No disclosed FDA warnings or layoffs; private status limits public disclosure, so conduct reference checks to verify stability.
Recent peer-reviewed publications with author affiliations at this company